217. Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70(3), 229–240. doi:10.1016/s0165-0327(01)00356-1.
218. Apter, D., Borsos, A., Baumgärtner, W. et al. (2003). Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms. European Journal of Contraception and Reproductive Health Care, 8(1), 37–51. doi:10.1080/713604397; Chiou, C., Trussell, J., Reyes, E. et al. (2003). Economic analysis of contraceptives for women. Contraception, 68(1), 3–10. doi:10.1016/s0010-7824(03)00078-7; Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (2001). Concurrent use of oral contraceptives with antidepressants for premenstrual syndromes. Journal of Clinical Psychopharmacology, 21(5), 540–542. doi:10.1097/00004714-200110000-00018; Schultz-Zehden, B., & Boschitsch, E. (2006). User experience with an oral contraceptive containing ethinylestradiol 30μg 30and drospirenone 3mg (Yasmin®) in clinical practice. Treatments in Endocrinology, 5(4), 251–256. doi:10.2165/00024677-200605040-00006; Short, M. (2009). User satisfaction with the combined oral contraceptive drospirenone 3 mg/ethinylestradiol 20 μg (Yasminelle®) in clinical practice. Clinical Drug Investigation, 29(3), 153–159. doi:10.2165/00044011-200929030-00002.
219. Lopez, L., Kaptein, A., & Helmerhorst, F. (2012). Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.cd006586. Cheslack-Postava, K., Keyes, K. M., Lowe, S. R., & Koenen, K. C. (2015). Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. Archives of Women’s Mental Health, 18(1), 103–111. doi:10.1007/s00737-014-0453-4.
220. Kurshan, N., & Epperson, C. N. (2006). Oral contraceptives and mood in women with and without premenstrual dysphoria: A theoretical model. Archives of Women’s Mental Health, 9(1), 1–14. doi:10.1007/s00737-005-0102-z; Genazzani, A. R., Stomati, M., Morittu, A.et al. (2000). Progesterone, progestagens and the central nervous system. Human Reproduction, 15(Suppl. 1), 14–27. doi:10.1093/humrep/15.suppl_1.14; Rapkin, A., Morgan, M., Goldman, L. et al. (1997). Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstetrics and Gynecology, 90(5), 709–714. doi:10.1016/s0029-7844(97)00417-1; Sundström, I., Andersson, A., Nyberg, S. et al. (1998). Patients with premenstrual syndrome have a different sensitivity to a neuroactive steroid during the menstrual cycle compared to control subjects. Neuroendocrinology, 67(2), 126–138. doi:10.1159/000054307.
221. Abraham, S., Luscombe, G., & Soo, I. (2003). Oral contraception and cyclic changes in premenstrual and menstrual experiences. Journal of Psychosomatic Obstetrics and Gynecology, 24(3), 185–193. doi:10.3109/01674820309039672; Bäckström, T., Hansson-Malmström, Y., Lindhe, B. et al. (1992). Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception, 46(3), 253–268. doi:10.1016/0010-7824(92)90006-f; Svendal, G., Berk, M., Pasco, J. A. et al. (2012). The use of hormonal contraceptive agents and mood disorders in women. Journal of Affective Disorders, 140(1), 92–96. doi:10.1016/j.jad.2012.03.030; Oinonen, K. A., & Mazmanian, D. (2002). To what extent do oral contraceptives influence mood and affect? Journal of Affective Disorders, 70(3), 229–240. doi:10.1016/s0165-0327(01)00356-1.
Глава 9
222. Khalili, H., Granath, F., Smedby, K. E. et al. (2016). Association between long-term oral contraceptive use and risk of Crohn’s disease complications in a nationwide study. Gastroenterology, 150(7), 1561–1567.e1. http://doi.org/10.1053/j.gastro.2016.02.041; Khalili, H., Higuchi, L. M., Ananthakrishnan, A. N. et al. (2013). Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut, 62(8), 1153–1159. http://doi.org/10.1136/gutjnl-2012-302362.
223. Falony, G., Joossens, M., Vieira-Silva, S. et al. (2016). Population-level analysis of gut microbiome variation. Science, 352(6285), 560–564. doi:10.1126/science.aad3503.
224. Fichorova, R. N., Chen, P., Morrison, C. S. et al. (2015). The contribution of cervicovaginal infections to the immunomodulatory effects of hormonal contraception. mBio, 6(5). doi:10.1128/mbio.00221-15.
225. Kudielka, B., Buske-Kirschbaum, A., Hellhammer, D., & Kirschbaum, C. (2004). HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: Impact of age and gender. Psychoneuroendocrinology, 29(1), 83–98. doi:10.1016/s0306-4530(02)00146-4.
226. Wiegratz, I., Lee, J., Kutschera, E. et al. (2002). Effect of dienogest-containing oral contraceptives on lipid metabolism. Contraception, 65(3), 223–229. doi:10.1016/s0010-7824(01)00310-9.
227. U.S. Department of Education, National Center for Education Statistics, National Center for Education Statistics, Higher Education General Information Survey, & Institute of Education Sciences. (2017). Table 303.70: Total undergraduate fall enrollment in degree-granting postsecondary institutions, by attendance status, sex of student, and control and level of institution: Selected years, 1970 through 2026. In U.S. Department of Education, National Center for Education Statistics (Ed.), Digest of Education Statistics (2017 ed.). Retrieved from https://nces.ed.gov/programs/digest/d16/tables/dt16_303.70.asp.
